W.L. Gore & Associates announced today that the FDA approved its Viabahn Fortegra venous stent, formerly known as Viafort.

Although the formation of collaterals is classically regarded as a compensatory mechanism to bypass and thus alleviate an obstruction, the mechanism and inducement of collateral formation are unknown.

FDA approves first venous stent for IVC and iliofemoral veins, offering a new treatment for deep venous disease with proven 12-month patency.

ABBOTT PARK, Ill., Aug. 7, 2012 /PRNewswire/ -- Abbott today announced that the U.S. Food and Drug Administration (FDA) approved the Omnilink Elite ® Vascular Balloon-Expandable Stent System for the ...

NATICK, Mass., Oct. 23, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports twelve-month clinical endpoint data from the ORION trial, which demonstrated robust safety and ...

Please provide your email address to receive an email when new articles are posted on . HOLLYWOOD, Fla. — Approved by the FDA in late January, the first balloon-expandable stent graft with an ...

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates (Gore) has announced that the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) has received U.S. Food & Drug ...

According to a retrospective study, iliac vein compression appears to be a promoter of, but not a cause of, iliac deep vein thrombosis. “The clinical significance of this study is that endovascular ...

Iliac venous outflow obstruction has an important role in the expression of symptomatic chronic venous insufficiency. This anatomic obstruction is frequently overlooked, owing in part to diagnostic ...